MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

[1]  F. Ansaldi,et al.  Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. , 2009, Vaccine.

[2]  Thomas Breuer,et al.  Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. , 2008, Vaccine.

[3]  A. Hoes,et al.  Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program. , 2008, Vaccine.

[4]  L. Sticchi,et al.  Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. , 2008, Vaccine.

[5]  J. Díez-Domingo,et al.  Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. , 2007, Vaccine.

[6]  F. Granath,et al.  Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area , 2007, European Respiratory Journal.

[7]  A. Floreani,et al.  Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases , 2007, Journal of Clinical Immunology.

[8]  A. Floreani,et al.  Response to influenza vaccine in people with non-protective HI antibody titers , 2006, European Journal of Epidemiology.

[9]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[10]  Cécile Viboud,et al.  Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.

[11]  M. Singh,et al.  MF59: A Safe and Potent Adjuvant for Human Use , 2006 .

[12]  R. Gasparini,et al.  Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects , 2004, European Journal of Epidemiology.

[13]  M. Goldman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vaccination and Autoimmune Disease: What Is the Evidence? , 2022 .

[14]  A. Podda,et al.  A New MF59-Adjuvanted Influenza Vaccine Enhances the Immune Response in the Elderly with Chronic Diseases: Results from an Immunogenicity Meta-Analysis , 2003, Gerontology.

[15]  L. Biasio,et al.  Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. , 2003, Vaccine.

[16]  V. Schijns.  Immunopotentiators in modern vaccines , 2003 .

[17]  A. Floreani,et al.  Comparison of three different influenza vaccines in institutionalised elderly. , 2001, Vaccine.

[18]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[19]  M. Faccini,et al.  Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. , 1999, Vaccine.

[20]  A. Podda,et al.  Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. , 1999, Vaccine.

[21]  J. Martin.  Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. , 1997, Biologicals : journal of the International Association of Biological Standardization.